ReviewInternational journal of cardiology. Congenital heart disease2022
Tricuspid valve: Once disregarded, now acknowledged.
Review in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Outcomes of Surgical and Transcatheter Interventions for Tricuspid Regurgitation: A Comprehensive Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Tricuspid Valve (TV) has been a subject of increasing clinical and research interest over the last century due to recognition of the importance of right heart (RH) disease. In this review we have emphasised the concept of the RH as a single functioning unit under normal and altered loading conditions. The complex structure of the RH is reflected in schematic illustrations to broaden understanding outside of the echo laboratory. We have examined the current TR classification model in pursuit of generating research into whether a separate "pacing lead TR" subtype should be considered. The impact of TR on outcomes and most of current treatment strategies have also been covered. We hope this can be widely utilised by internists, cardiologists, cardiac surgeons, general practitioners, and clinical cardiac physiologists alike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.